AstraZeneca’s Enhertu cuts progression risk 37% in first-line HER2-mutant lung cancer as survival question remains open
Enhertu reduced the risk of progression or death by 37% against pembrolizumab plus chemotherapy in first-line HER2-mutant metastatic non-small cell lung cancer, potentially opening another earlier-treatment market for AstraZeneca and Daiichi Sankyo.